{"id":37157,"date":"2019-04-11T17:15:00","date_gmt":"2019-04-11T15:15:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&p=37157"},"modified":"2023-09-07T17:16:08","modified_gmt":"2023-09-07T15:16:08","slug":"clementia-pharmaceuticals-inc-announces-receipt-of-final-court-approval-for-plan-of-arrangement-with-ipsen-s-a","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/clementia-pharmaceuticals-inc-announces-receipt-of-final-court-approval-for-plan-of-arrangement-with-ipsen-s-a\/","title":{"rendered":"Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A."},"content":{"rendered":"\n
April 11, 2019 at 12:00 PM EDT<\/p>\n\n\n\n
MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) \u2014 Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (\u201cClementia\u201d or the \u201cCorporation\u201d) is pleased to announce that the Qu\u00e9bec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act <\/em>pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration\u2019s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.<\/p>\n\n\n\n